Evidence map›Paper›PMID 33620016›Full record

Trial reportAnnals of medicine2021

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.

Chuan Li, Fengming Luo, Chengwu Liu, Nian Xiong, Zhihua Xu, Wei Zhang, Ming Yang, Ye Wang, Dan Liu, Chao Yu and 17 more

Registry-linked trialOpen access · goldAbstract readLetterMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05381363 (Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children), which is not on this map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05381363 phase1 / phase2terminatednot on this mapstarted 2022, after this paper: background citation

Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2022 to 2023Enrolled24ConditionsCOVID-19, ChildrenArmsInhaled Interferon α2b, Standard of Care
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Immune-based therapeutic approaches in COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  9. Review
  10. Article
  11. Specialized interferon action in COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. The immunology and immunotherapy for COVID-19.Expert reviews in molecular medicine · 2021
    Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 8 institutions in 3 countries.

Chuan LiDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Fengming LuoDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Chengwu LiuDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Nian XiongDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhihua XuDepartment of Critical Care Medicine, Mianyang Central Hospital, Mianyang, China.
Wei ZhangDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital, The Second Military Medical University, Shanghai, China.
Ming YangDepartment of Respiratory Medicine, The Public Health Clinical Center of Chengdu, Chengdu, China.
Ye WangDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Dan LiuDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Chao YuDepartment of Infectious Diseases, Guanggu District, the Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
Jia ZengDepartment of Infectious Diseases, Guanggu District, the Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
Li ZhangDepartment of Respiratory Disease, Wuhan Red Cross Hospital, Wuhan, China.
Duo LiDepartment of Respiratory Disease, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Yanbin LiuCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Mei FengDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Ruoyang LiuDepartment of Respiratory Disease, Sichuan Second Hospital of T. C. M, Chengdu, China.
Jiandong MeiDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Senyi DengDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Zhen ZengDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Yuanhong HeDepartment of Infectious Disease, The Public Health Clinical Center of Chengdu, Chengdu, China.
Haiyan LiuDepartment of Tuberculosis, The Public Health Clinical Center of Chengdu, Chengdu, China.
Zhengyu ShiDepartment of Tuberculosis, The Public Health Clinical Center of Chengdu, Chengdu, China.
Meng DuanDepartment of Liver Disease, The Public Health Clinical Center of Chengdu, Chengdu, China.
Deying KangDepartment of Evidence based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China.
Jiayu LiaoDepartment of Bioengineering, Bourns College of Engineering, University of California, Riverside, CA, USA.
Weimin LiDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Lunxu LiuDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Sichuan University · CNWest China Hospital of Sichuan University · CNPublic Health Clinical Center of Chengdu · CNHubei Provincial Women and Children's Hospital · CNWuhan Red Cross Hospital · CNAffiliated Hospital of Southwest Medical University · CNMianyang Central Hospital · CNSecond Hospital of Nanchang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. To compare the effectiveness of a novel genetically engineered recombinant super-compound interferon (rSIFN-co) with traditional interferon-alpha added to baseline antiviral agents (lopinavir-ritonavir or umifenovir) for the treatment of moderate-to-severe COVID-19.

methodIn this multicenter randomized (1:1) trial, patients hospitalized with moderate-to-severe COVID-19 received either rSIFN-co nebulization or interferon-alpha nebulization added to baseline antiviral agents for no more than 28 days. The primary endpoint was the time to clinical improvement. Secondary endpoints included the overall rate of clinical improvement assessed on day 28, the time to radiological improvement and virus nucleic acid negative conversion.

resultsA total of 94 patients were included in the safety set (46 patients assigned to rSIFN-co group, 48 to interferon-alpha group). The time to clinical improvement was 11.5 days versus 14.0 days (95% CI 1.10 to 2.81, CONCLUSIONS AND RELEVANCE: rSIFN-co was associated with a shorter time of clinical improvement than traditional interferon-alpha in the treatment of moderate-to-severe COVID-19 when combined with baseline antiviral agents. rSIFN-co therapy alone or combined with other antiviral therapy is worth to be further studied.Key messagesThere are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. Interferon alphas, by inducing both innate and adaptive immune responses, have shown clinical efficacy in treating severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus.In this multicenter, head-to-head, randomized, clinical trial which included 94 participants with moderate-to-severe COVID-19, the rSIFN-co plus antiviral agents (lopinavir-ritonavir or umifenovir) was associated with a shorter time of clinical improvement than interferon-alpha plus antiviral agents.

Indexed as

COVID-19 Drug TreatmentAdultAntiviral AgentsClinical ProtocolsCOVID-19Drug Therapy, CombinationFemaleHumansInterferon-alphaInterferon beta-1bMaleMiddle AgedRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeAntiviral Agentsinterferon alfacon-1Interferon-alphaInterferon beta-1bRecombinant ProteinsCOVID-19interferon-alpharecombinant super-compound interferonSARS-CoV-2treatment

Identifiers

PMID33620016
PMCPMC7906612
OpenAlexW3132736860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.